Shire PLC (LON:SHP) had its price objective trimmed by HSBC from GBX 5,250 ($68.53) to GBX 5,200 ($67.88) in a report issued on Wednesday. The firm currently has a hold rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on SHP. Deutsche Bank AG reissued a buy rating and set a GBX 5,600 ($73.10) price objective on shares of Shire PLC in a report on Tuesday, May 31st. Credit Suisse Group AG reaffirmed an outperform rating and issued a GBX 5,000 ($65.27) target price on shares of Shire PLC in a report on Wednesday, June 1st. JPMorgan Chase & Co. reaffirmed an overweight rating and issued a GBX 5,600 ($73.10) target price on shares of Shire PLC in a report on Wednesday, June 1st. Morgan Stanley reaffirmed an overweight rating and issued a GBX 5,600 ($73.10) target price on shares of Shire PLC in a report on Friday, June 3rd. Finally, Jefferies Group lifted their target price on shares of Shire PLC from GBX 5,150 ($67.22) to GBX 6,050 ($78.97) and gave the company a buy rating in a report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5119.00 on Wednesday. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The firm’s 50-day moving average is GBX 4,990.28 and its 200-day moving average is GBX 4,501.92. The firm’s market cap is GBX 34.95 billion.
The company also recently announced a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be paid a GBX 3.51 ($0.05) dividend. This represents a yield of 0.07%. The ex-dividend date is Thursday, September 8th.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.